论文部分内容阅读
目的:探讨香菇多糖联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎(chronic hepatitis B,CHB)的临床疗效。方法:选取90例HBeAg阳性CHB患者,将其随机分为观察组和对照组各45例,分别给予香菇多糖联合恩替卡韦治疗以及单纯恩替卡韦治疗,比较两组患者的AST、ALT复常以及HBeAg转阴率。结果:治疗3个月以及6个月后观察组患者的ALT和AST复常率以及HBeAg转阴率比对照组高(P<0.05),治疗12个月后两组的复常率无明显差异(P>0.05)。结论:香菇多糖可在相对较短时间内显著提高HbeAg阳性CHB患者肝功能复常率和HbeA转阴率,显著提高恩替卡韦抗乙肝病毒疗效。
Objective: To investigate the clinical efficacy of lentinan combined with entecavir in the treatment of HBeAg-positive chronic hepatitis B (CHB). Methods: Ninety patients with HBeAg positive CHB were randomly divided into observation group and control group, 45 cases were treated with lentinan combined with entecavir and entecavir alone. AST, ALT normalization and HBeAg negative were compared between the two groups rate. Results: The normalization rate of ALT and AST and the negative rate of HBeAg in the observation group were higher than those in the control group (P <0.05) after treatment for 3 months and 6 months. There was no significant difference in the normalization rate between the two groups after 12 months of treatment (P> 0.05). Conclusion: Lentinan can significantly improve the rate of liver function abnormality and HbeA negative rate in HbeAg positive CHB patients in a relatively short period of time, and significantly improve the efficacy of entecavir against hepatitis B virus.